摘要
目的探讨滋肾化瘀汤应用在子宫宫腔手术后腔内粘连(IUA)的临床疗效以及对细胞因子信号转导抑制因子3(SOCS3)及雌激素受体(ER)表达的影响。方法行宫腔操作的64例患者根据入院顺序随机分为试验组和对照组,每组32例,对照组采用口服雌激素预防宫腔粘连,试验组采用滋肾化瘀汤预防宫腔粘连,由同一中医师随访2组患者治疗前后中医证候改善情况,治疗后子宫内膜厚度,比较宫腔镜查看粘连分度、例数及总的发生率,应用免疫组化的方法检测2组患者的宫腔粘连组织中SOCS3和ER的表达状况。结果治疗后,试验组患者的中医证候改善、月经恢复、子宫内膜厚度、宫腔再发粘连等与对照组比较,差异有统计学意义(P<0.05);试验组患者的SOCS3和ER的表达明显低于对照组,差异有统计学意义(P<0.05)。结论滋肾化瘀汤在预防宫腔术后腔内粘连、促进子宫内膜功能恢复、抑制SOCS3和ER的表达等等各个方面具有明显的优势,值得临床应用。
Objective To investigate the clinical efficacy of Zishenhuayu decoction in treatment of intrauterine adhesions(IUA)after uterine hysterectomy and its effects on the expression of cytokine signal transduction inhibitor 3(SOCS3)and estrogen receptor(ER).Methods A total of 64 patients who underwent uterine operation in our hospital from December 2008 to June 2018 were randomly divided into experimental group(n=32)and control group(n=32)according to the order of admission.The patients in control group were treated by oral estrogen to prevent intrauterine adhesions,however,the patients in experimental group were treated by Zishenhuayu decoction to prevent intrauterine adhesions.The improvement status of TCM syndromes before and after treatment was observed by the same Chinese medicine practitioner.Moreover the endometrial thickness was observed after treatment.The adhesion index,number of cases and total incidence were observed by hysteroscopy.In addition the expression levels of SOCS3 and ER in the intrauterine adhesion tissues were detected by immunohistochemistry.Results After treatment,there were significant differnces in the improvement status of TCM syndromes,menstruation recovery,endometrial thickness,and recurrence of uterine cavity adhesions between the two groups(P<0.05).The expression levels of SOCS3 and ER in experimental group were significantly lower than those in control group(P<0.05).Conclusion Zishenhuayu decoction has obvious advantages in preventing intraluminal adhesion after uterine cavity surgery,promoting endometrial function recovery,inhibiting the expressions of SOCS3 and ER,therefor,it is worthy of clinical application.
作者
梁红霞
许建多
毛丽梅
刘丹丹
杜晓静
来于
LIANG Hongxia;XU Jianduo;MAO Limei(Shijiazhuang Hospital for Maternal and Child Health,Hebei, Shijiazhuang 050000,China)
出处
《河北医药》
CAS
2020年第2期216-219,共4页
Hebei Medical Journal
基金
河北省中医药管理局科研计划项目(编号:2018245)
关键词
滋肾化瘀汤
宫腔粘连
细胞因子信号转导抑制因子3
雌激素受体
Zishenhuayu decoction
intrauterine adhesions
cytokine signal transduction inhibitor 3
estrogen receptor
